Introduction

Nasopharyngeal carcinoma (NPC) is a common malignant tumor in China, related with Epstein-Barr virus infection, dietary, genetic predisposition and environmental factors (1). Radiotherapy is the first choice for NPC patients, however the five-year survival rate is only about 25% because of radioresistance (2).

During the past decade, emerging evidence has suggested curcumin was a promising drug in cancer prevention and...
therapy. Furthermore, some investigations have revealed curcumin was a chemosensitizer and radiosensitizer in many cancers, including breast cancer, colon and gastric cancer, pancreatic cancer, head and neck cancer, brain cancer in vivo and in vitro (3-5). But the most important defect of curcumin is its low bioavailability in humans (6,7). To improve the bioavailability of curcumin, novel curcumin analogue has been evaluated. T63 is one of the new 4-arylidene curcumin analogues (Figure 1A), which has been reported by Qiu et al. (8). It has demonstrated that the tumorigenic potential of lung cancer cells was affected by T63 (9).

In our study, we investigated the anti-cancer activity of T63 on NPC cells for the first time. We also explored its significant effect on radioresistant NPC cell line (CNE2R) in order to suggest T63 could be a potential drug for NPC patients with radioresistance. The results of this study could provide scientific basis and technology support for NPC therapy.

Methods

Chemicals and reagents

T63 was synthesized by the School of Pharmaceutical Sciences, Sun Yat-sen University (Guangzhou, China). Propidium iodide (PI), 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) and Rhodamine123 were obtained from Sigma-Aldrich Chemical Company (Sigma-Aldrich, St. Louis, MO). Hoechast33342 was purchased from Molecular Probes (Life Technologies, USA). The fluorescein isothiocyanate-labeled AnnexinV/propidium iodide Apoptosis Detection Kit was purchased from Roche (Roche Diagnostics, Indianapolis, USA). The following proteins were evaluated by western blotting: Bcl-2 (Cell Signaling Technology Cat# 15071, RRID: AB_2744528), Bax (Cell Signaling Technology Cat# 2774, RRID: AB_490806), Caspase-8, -9, -3 (#4790, RRID: AB_10545768); #9502, RRID: AB_2068621; #9662, RRID: AB_331439; Cell Signaling, USA), p-Akt p473 (Antibodies-Online Cat# ABIN461540, RRID: AB_10805010), Akt (Cell Signaling Technology Cat# 9272, RRID: AB_329827), PARP (Cell Signaling Technology Cat# 7858, RRID: AB_1264143), Cyclin D1 (Cell Signaling Technology Cat# 2922, RRID: AB_2228523), p21 (Cell Signaling Technology Cat# 2947, RRID: AB_823586), p27 (Cell Signaling Technology Cat# 3686, RRID: AB_2077850) and β-actin (Multi Sciences Cat# 70-ab008-100, RRID: AB_2750915). The ECL Western blot analysis reagents were purchased from Pierce Biotech (Rockford, IL, USA).

Cell culture

Two kinds of NPC cell lines (CNE2 and the stable radioresistant NPC cell line CNE2R) were obtained from Cancer Center, Sun Yat-sen University (Guangzhou, China) and our lab (10), cultured in RPMI1640 medium supplemented with 10% FBS, and incubated under conditions of 5% CO₂ at 37 °C.

Cell viability assay

The cultured cells in the 96-well microplates (6,000 cells/well) were treated with various concentrations (0–1.0 μM) of T63, and incubated for 24, 48, and 72 h. Then, cells from each well were solubilized using 150 μL DMSO after incubation with the MTT reagent for 4 h, and absorbance of the samples was measured using a microplate reader at a wavelength of 570 nm.

Colony formation assay

For the colony formation assay, the cells treated with 0.05, 0.1 and 0.2 μM T63 for 48 h were plated onto cell culture dishes, with a diameter of 6 cm, at a density of 500 cells/well and maintained for 14 d. Visible colonies (containing >50 cells) were identified through Giemsa staining.

Morphological changes

The cells were plated into 6-well plates at a density of 2×10⁵ cells/well overnight, and then divided into four groups (control, 0.1 μM group, 0.5 μM group, 1.0 μM group). After 48 h, cells were fixed with methanol, then stained with 10 μg/mL Hoechst33342 for 15 min and washed by PBS. A fluorescence microscope (Leica DMI4000B, Germany) was used to observe apoptotic morphologic changes.

Flow cytometric analysis of cell cycle and apoptosis

CNE2 and CNE2R cells (3×10⁶ cells/well) were treated with different concentrations of T63 (0.1, 0.3 and 0.5 μM) in 6-well plates for 24 h. The treated cells were harvested,
fixed overnight in cold 70% ethanol at 4 °C, washed twice
with chilled PBS, incubated with 100 µL RNAase (final
concentration, 20 µg/mL) at 37 °C for 30 min, and stained
using 400 µL of propidium iodide (PI; final concentration,
50 µg/mL) for 30 min. The labeled cells were analyzed
by flow cytometry using the ModFit Software (Verity
Software House Inc., USA). Additionally, the fluorescein
isothiocyanate-labeled AnnexinV/propidium iodide
Apoptosis Detection Kit was used to analyze the apoptosis
of CNE2 and CNE2R cells treated with T63 according to
the manufacturer’s instructions. A FACScan flow cytometer
with The Cell Quest software was used for data acquisition
and analysis.

**Flow cytometric analysis of mitochondrial membrane
potential**

Mitochondrial membrane potential was measured using
flow cytometry with the fluorescent probe rhodamine123
(Rh123). Rh123 accumulated in normal mitochondrial
due to its high negative charge. Loss of mitochondrial
transmembrane potential led to the release of Rh123 and a
reduction in its fluorescence intensity. Rh123 was prepared
in PBS to a final concentration of 5 µg/mL. Exponentially
growing CNE2 and CNE2R cells were seeded into 6-well
plates at a density of 2×10^5 cells overnight. T63 was added
at different final concentrations. In control group, equal
volume of RPMI1640 medium was added. After incubating
for 16 h, cells were harvested by trypsin and washed with
PBS. The Rh123 (5 µg/mL) were added into the cells and
incubated at 37 °C in an incubator containing 5% CO₂
for 30 min. Then samples were centrifuged and washed with
cold PBS twice. The samples were resuspended in 1 mL
PBS and analyzed by flow cytometry. The experiment was
repeated three times.

**Western blotting**

Western blotting was used for analyzing specific proteins.
NPC cells were cultured in complete medium for 12 h
followed by different concentrations of T63 (0.4, 0.8, and
1.6 µM). Then the incubation was carried out for 48 h.
After the indicated incubation period, cells were harvested
by scraping from culture dishes, lysed in 1x sampling buffer
(Cell signaling Technology, Danvers, MA) with protease
inhibitor cocktail (Roche) and collected by centrifugation.
The samples were loaded on SDS-polyacrylamide gradient
gels (8%, 10%, 12% and 15%) (Bio-Rad, Hercules, CA),
and electrophoretically transferred to polyvinylidene
fluoride (PVDF) membranes (EMD Millipore, Billerica,
USA). Membranes were blocked with fat-free milk powder
(Roche) (5%, w/v) and Tween 20 (1%, w/v) in TBS-T for
1 h. Each membrane was incubated with primary antibodies.

**Statistical analysis**

Each experiment was performed at least in triplicates. The
data are presented as the mean ± SD. All statistical analyses
were performed using the SPSS 11.0 software and P values
of <0.05 were considered to be statistically significant.

**Results**

**Effects of T63 on cell viability**

As shown in **Figure 1B**, after treatment with T63 for 24,
48 and 72 h, IC50 values were 1.62±0.11, 0.51±0.09, 0.34±
0.06 µM for CNE2, and 1.53±0.09, 0.37±0.04, 0.14±
0.04 µM for CNE2R. We demonstrated that T63 decreased
the viabilities of CNE2 and CNE2R cells in a dose- and
time-dependent manner (P<0.05 and P<0.01, respectively).
The MTT assay showed that T63 significantly inhibited
the viabilities of CNE2 and CNE2R cells (**Figure 1C,D**).
Clearly, after treatment with T63 for 48 h, the cytotoxicity
in CNE2R cells was stronger than that in CNE2 cells.
Consistent with the MTT results, colony formation assay
(**Figure 2A**) showed that T63 significantly inhibited
the focus numbers of both CNE2 and CNE2R cells, but
there were no significant differences between CNE2 and
CNE2R.

**Effect of T63 on morphologic changes**

The morphologic changes of cells treated with different
concentrations of T63 (0.1, 0.5, and 1.0 µM) were observed
under fluorescence microscope by Hochest33342 staining.
As shown in **Figure 2B**, typical morphological changes, such
as chromatin condensation and the formation of apoptotic
bodies, appeared after treatment with 0.5 µM T63 for 48 h,
whereas the vehicle treated cells did not show evident
apoptotic morphological changes.

**Effects of T63 on cell cycle and apoptosis**

DNA cell cycle analysis was performed to estimate the effect
of T63 on the distribution of CNE2 and CNE2R cells in
cell cycle. As shown in Figure 3A, compared with control, both CNE2 and CNE2R cells exhibited accumulation of cells in the G2/M phase accompanied by a decrease in S phase in a dose-dependent way upon T63 treatment. The percentage of cells in the G2/M phase increased six-fold when cells were treated with 0.5 µg/mL of T63, and there was no significant difference between CNE2 and CNE2R cells.

The morphologic changes suggested that T63 induced cell apoptosis. We performed AnnexinV-FITC/PI double staining and the population of apoptotic cells was analyzed by flow cytometry. As shown in Figure 3B, 6.42%±0.31% cells were positive for AnnexinV-FITC staining in control group, while after treatment with T63 apoptotic cells increased to 10.41%±0.44%, 12.93%±0.75% and 14.62%±0.37% at 0.1, 0.3 and 0.5 µM respectively (P<0.05). T63 induced more effective apoptosis in CNE2R than CNE2. The apoptotic rate increased from 7.20%±0.47% to 15.26%±0.53%, 22.48%±1.34% and 44.94%±1.92% at 0.1, 0.3 and 0.5 µM T63 respectively (P<0.05).

Effect of T63 on mitochondrial membrane potential

We used Rh123, which accumulated within mitochondria in a potential-dependent manner to further verify T63 induced a loss of mitochondrial membrane potential. As shown in Figure 3C, treatment with different concentrations of T63 (0.1, 0.3 and 0.5 µM) resulted in a dose-dependent decrease (P<0.05 and P<0.01, respectively) in the fluorescence density. Collectively, the data suggested that T63 induced apoptosis in both CNE2 and CNE2R cells through disruption of the mitochondrial membrane potential and a significant difference was found between CNE2 and CNE2R cells (P<0.05).

Effect of T63 on apoptotic pathways

We performed western Blotting and detected some apoptotic proteins in both cells after treatment with T63 for 48 h. As shown in Figure 4, we found that the expression level of cleaved PARP increased significantly. The
cytochrome-c in the cytosol also increased. Then we found levels of procaspase-8, procaspase-9, and procaspase-3 decreased in a dose-dependent way. And the level of cleaved caspase-3, -8, -9 enhanced remarkably as the same manner.

Effect of T63 on PTEN/PI3K/Akt pathway

Based on our experimental results and previously available data in literature, some proteins involved in the T63-mediated induction of apoptosis were investigated. As shown in Figure 5, the levels of the anti-apoptotic protein, Bcl-2 decreased in CNE2 and CNE2R cells treated with T63, whereas the level of the pro-apoptotic protein Bax increased. Thus the ratio of Bcl-2/Bax decreased after treatment with T63. T63 treatment resulted in an increase of PTEN in CNE2R and inhibition of p-Akt\textsuperscript{473} for both NPC cell lines. The levels of Cyclin D1 was found to be significantly inhibited in cells with T63, while the levels of p21 and p27 were increased (Figure 6).

Discussion

To improve the anticancer effect of curcumin, Qiu et al. identified the new 4-arylidene curcumin analogue, T63. It had some wonderful qualities comparing with the curcumin, such as low micromolar concentrations, good anticancer potential and bioavailability. Surprisingly, T63 exhibited thirtyfold higher in inhibition potency against lung cancer cells than curcumin (8). T63 significantly suppressed the growth of A549 lung cancer xenograft tumors, associated
with proliferation suppression and apoptosis induction in tumor tissues, without inducing any notable major organ-related toxicity (9). T63 exhibited significantly improved potency in blocking the nuclear factor kB pathway by both in vivo and in vitro kinase assays and pathway analysis (10). We supposed T63 might be a promising anticancer agent with other cancers. Till now, there was no report to suggest its anticancer effect on NPC cells. The mechanisms of T63 need to be explored for NPC cells.

As we all known, curcumin exhibits significant anticancer effect on many tumors in vivo and in vitro. Lin et al. found that the IC_{50} value of curcumin on human NPC was 50 μM for 48 h (11). It also reported that pretreatment with 3.5 μM curcumin can decrease the cell counts by clonogenic assay at 2.5 Gy of radiation, although this concentration did not decrease the ability to form colonies in the absence
of radiation (12). In our study, T63 exerted good growth-inhibitory effect in human NPC, and the IC$_{50}$ values of CNE2 and CNE2R cells were 0.51 and 0.37 μM respectively for 48 h. T63 exhibited obviously high inhibition potency in NPC cells, especially of radioresistant cells.

T63 may contribute to the accumulation of p21 and p27, which binds and inactivates the Cyclin D-CDK complexes, and then leads to cell cycle arrest in the G0/G1 phase and subsequent apoptosis. Koo et al. demonstrated that

Figure 4 Western blotting measured apoptosis-related proteins including 55 kDa procaspase-8, 18 kDa and 10 kDa cleaved caspase-8, 45 kDa procaspase-9, 35 kDa cleaved caspase-9, 15 kDa cytochrome-c, 32 kDa procaspase-3, 19 kDa and 17 kDa cleaved caspase-3 and 89 kDa cleaved-PARP in CNE2 and CNE2R cells after T63 treatment at different concentrations for 48 h; 42 kDa β-actin was used as an internal control. The student’s t-test was performed to compare the rates of two cell lines’ colony formation, and one-way analysis of variance when more than two groups.

Figure 5 Western blotting analysis of 55 kDa PTEN, 57kDa Akt, 57 kDa p-Akt, 21 kDa Bax and 26 kDa Bcl-2 in CNE2 and CNE2R cells were detected as shown. On the right, ratio changes of Bcl-2/Bax with their densities in Western blotting were presented as column.
Curcumin inhibited proliferation of human gastric cancer cells by blocking the G2/M transition (13). Inhibiting cancer cells in G2/M phase of the cell cycle can make radiation more effective (12). We found T63 was able to promote cell cycle arrest in G2/M phase. But, no significant differences were found between CNE2 and CNE2R cells. As reported, the G2/M phase was related to DNA synthesis and the mitotic preparation period, and G2/M arrest led potentially to apoptosis (14). Therefore, the effect of apoptosis might partly be associated with T63’s ability to block cells in G2/M cell cycle phase. Our results showed a significant increase in apoptosis by AnnexinV-FITC/PI double staining, especially in CNE2R cells. It indicated T63 might be a potential anticancer drug for radioresistant NPC cells. Furthermore, we observed the morphological changes of NPC cells upon T63 treatment. All data demonstrated the pro-apoptotic effect of T63 on both radiosensitive and radioresistant NPC cells.

The mitochondria-mediated apoptosis pathway is referred to as the intrinsic apoptosis pathway, and it plays a central role in apoptosis induced by the caspase-dependent pathway (15). Our results showed that one of the early events in the apoptotic process induced by T63 was mitochondrial depolarization and loss of mitochondrial membrane potential in CNE2 and CNE2R cells, and the changes in CNE2R were more obvious than in CNE2 cells (P<0.05) (Figure 3C). Apoptosis stimuli can cause mitochondrial membrane potential loss and cytochrome-c release from the mitochondria to the cytosol (16). We detected cytochrome-c in the cytosol increased in a dose-dependent manner (Figure 4). Then in the cytosol, cytochrome-c activates caspase-3, after which specific substrates of caspase-3, such as PARP, are cleaved, eventually leading to apoptosis. To evaluate the apoptotic effect of T63, we detected some caspases, including caspase-8, caspase-9 and caspase-3 and cleaved PARP. Previous study reported that caspase-8 was the initiator of the death receptor pathway (17), and involved in mitochondria-mediated apoptosis via caspase-9 was the initiator of the mitochondrial-mediated apoptotic pathway (18). The PARP is the substrate for some caspases during apoptosis, which involved in DNA repair, genome surveillance, and maintenance of genomic integrity in response to environmental stress. Its cleaved protein is considered as an important biomarker of apoptosis. Moreover, caspase-3 is considered to be the central effector protein in the execution of apoptosis by cleaving PARP (19). Our results showed the decreases of procaspase-8, procaspase-9 and the increases of cleaved caspase-8 and cleaved caspase-9 in both CNE2 and CNE2R cells after treatment with T63 for 48 h. We also found the decrease of procaspase-3 and increase of cleaved caspase-3 and cleaved PARP (Figure 4). These results demonstrated that T63 can effectively induced apoptosis through mitochondria-mediated apoptosis pathway by activation of caspase proteins. Bcl-2 are key regulators of the mitochondria-mediated apoptosis. It is notable that T63 significantly decreased the expression levels of the anti-apoptotic Bcl-2 protein, and increased the expression levels of pro-apoptotic Bax proteins (Figure 5).

In order to explore the concrete apoptotic pathway of T63 pro-apoptotic effect, we detected the alteration of mitochondrial membrane potential and two important proteins PTEN and Akt on PI3K/Akt signaling pathway. PI3K/Akt is one of the most important signaling pathways in regulating cell proliferation, growth, apoptosis, survival and metabolism by phosphorylating a variety of substrates, and the inhibition of Akt phosphorylation has been suggested as a novel targeted for the reputeic agents in human cancer (20). Ou et al. demonstrated that...
radioresistance reduced in NPC involving Akt pathway (21). And it was reported that curcumin sensitized tumors to gamma radiation by down-regulating various growth regulatory pathways and specific genetic targets including Akt (4). PTEN is a well-known tumor suppressor gene mutated in a large number of cancers at high frequency, containing a tensin-like domain and a catalytic domain. Generally, PTEN acts as tumor suppressor by negatively regulating the Akt signaling pathway (22). The deregulation of PTEN contributes to tumor genesis, metastasis, and proliferation (23,24). To explore the role of Akt in pro-apoptotic effect of T63 on NPC cells especially of radioresistant NPC cells, we further detected the level of p-Akt\textsuperscript{\textit{S473}} and total Akt. We demonstrated that T63 directly targeted PTEN and promoted PTEN expression levels in CNE2 and CNE2R cells. And T63 inhibited the levels of p-Akt\textsuperscript{\textit{S473}} in a dose-dependent manner, which is similar with previous report (10). We demonstrated that PTEN was downregulated in NPC cells and directly targeted by T63, suggesting that the positive role of T63 in NPC cells may be represented by the down-regulation of the PI3K/Akt pathway.

The changes of Bcl-2/Bax accompanied by an arrest of cell cycle progression and apoptosis induction can be increased by the p-Akt\textsuperscript{\textit{S473}} (25). In response to the drug, the Bcl-2 family proteins congregate at intracellular membranes to adjudicate whether the cell should die, which are the hallmark of apoptosis regulation (26). Bax was shown to induce cell death, while Bcl-2 protected cell death from mitochondrial disruption (27). Bcl-2 protein family is possibly related to cancer pathophysiology and resistance to conventional chemotherapy and radiotherapy. Alternations in expression of the Bcl-2 family members could play a significant role in cell death (28). In our study, we found that the apoptotic protein Bax increased and the anti-apoptotic protein Bcl-2 decreased leading to a decrease in Bcl-2/Bax ratio (\textit{Figure 5}), which was the key event for apoptosis due to loss of mitochondrial potential and mitochondrial release cytochrome-c into the cytosol in CNE2 and CNE2R cells (28,29).

Conclusions

We demonstrated that T63 definitely induced apoptosis in both radiosensitive and radioresistant NPC cell lines. Furthermore, we found that T63 induced apoptosis mainly through mitochondrial dysfunction. We also suggested PI3K/Akt signaling pathway might be important effectors in the anticancer role of T63. Although the pathways involving with apoptosis were similar between CNE2 and CNE2R cells, the effect of mitochondria-mediated apoptosis was stronger on radioresistant cells than that on radiosensitive cells. In conclusion, T63 might be a promising anticancer drug for NPC treatment, especially for radioresistant NPC cells.

Acknowledgments

We thank professor Bu (School of Pharmaceutical Sciences, Sun Yat-sen University) for the drug.

Funding: This work is supported by the National Natural Science Foundation of China (81071837; 30670627); the Science and Technology Funding Project of Guangzhou, China (No. 2009Z1E2012).

References

2. Elser C, Siu LL, Winquist E, et al. Phase II trial of


Cite this article as: Liu Q, Chen W, Yang H. T63 induces apoptosis in nasopharyngeal carcinoma cells through mitochondrial dysfunction and inhibition of PI3K/Akt signaling pathway. Transl Cancer Res 2020;9(8):4635-4645. doi: 10.21037/tcr-20-1677